HIV vaccine trial could be ‘final nail in the coffin’ for disease
JOHANNESBURG >> A new vaccine against HIV, to be tested Wednesday in a trial to be launched in South Africa, could be “the final nail in the coffin” for the disease if it is successful, scientists say.
The study, called HVTN 702, aims to enroll 5,400 sexually active men and women aged between 18 and 35 at 15 sites across South Africa.
It will be the largest and most advanced HIV vaccine clinical trial to take place in South Africa, where more than 1,000 people a day are infected with HIV.
“If deployed alongside our current armory of proven HIV prevention tools, a safe and effective vaccine could be the final nail in the coffin for HIV,” Anthony Fauci, director of the U.S. government’s National Institute of Allergy and Infectious Diseases, said in a statement.
The new vaccine is based on a 2009 trial in Thailand, that was found to be 31.2 percent effective at preventing HIV infection.